According to current currency rates, Novavax Inc. (NASDAQ: NVAX) is trading at about USD $6.12 per share as of May 10, 2025, which is comparable to about AUD $9.32.
Recent Performance
Novavax’s stock has experienced significant volatility in recent sessions. On May 9, 2025, the stock closed at USD $5.98, marking a 10.29% decline from the previous day . The day’s trading range spanned from USD $5.80 to $6.64, with a trading volume of approximately 20 million shares .Companies Market Cap+3markets.businessinsider.com+3Investing.com+3Novavax Investor Relations | Novavax
Over the past 52 weeks, NVAX has fluctuated between a low of USD $4.43 and a high of USD $23.86 . This volatility reflects the company’s ongoing challenges in the competitive vaccine market.Investing.com Australia+2Stake+2Novavax Investor Relations | Novavax+2
Financial Snapshot
- Market Capitalization: Approximately USD $1.08 billion
- Earnings Per Share (TTM): USD -$1.918
- Year-over-Year Revenue Growth: -69.7%
- Profit Margin: -27.5% StakeWiseWise+4Yahoo Finance+4Investing.com+4
These figures indicate that Novavax is currently facing financial headwinds, with declining revenues and negative profit margins.
Analyst Outlook
Despite recent setbacks, some analysts maintain a cautiously optimistic view. The average price target for NVAX is USD $15.57, suggesting a potential upside of over 150% from current levels . However, technical indicators currently signal a “Strong Sell,” reflecting bearish market sentiment .Investing.com AustraliaInvesting.com
Investing from Australia
Australian investors interested in NVAX can access the stock through platforms like Stake, which offers exposure to U.S. markets. As of the latest data, NVAX is trading at AUD $9.32 per share .Stake+1Wise+1Wise